Related Experiment Video
Updated: Aug 14, 2026
15:23
Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
Published on: May 13, 2010
Selegiline for Alzheimer's disease
1Department of Clinical Geratology, University of Oxford, Oxford, UK, OX2 6HE. jacqueline.birks@geratology.ox.ac.uk
The Cochrane Database of Systematic Reviews
|January 22, 2003
Summary
Selegiline shows no clinically meaningful benefit for Alzheimer's disease patients, despite some short-term improvements in cognition and daily living activities. Further studies are not recommended due to disappointing results.
Area of Science:
- Neuroscience
- Gerontology
- Pharmacology
Background:
- Alzheimer's disease (AD) is the leading cause of dementia, affecting 60% of older adults with cognitive decline.
- Neurotransmitter dysfunctions are implicated early in AD pathogenesis.
- Selegiline's efficacy for AD symptoms is controversial, leading to limited prescription and regulatory approval.
Purpose of the Study:
- To evaluate selegiline's effectiveness in improving the well-being of Alzheimer's disease patients.
- To synthesize evidence from randomized controlled trials on selegiline for AD.
Main Methods:
- Systematic search of multiple databases (Cochrane, MEDLINE, PsycLIT, EMBASE) for randomized controlled trials (RCTs) of selegiline in dementia patients.
- Inclusion criteria: unconfounded, double-blind, RCTs comparing selegiline to placebo for >1 day.
- Individual patient data meta-analysis combined with published summary statistics from 17 included trials.
Main Results:
- Selegiline demonstrated statistically significant, but modest, improvements in cognition at 4-6 and 8-17 weeks.
- A significant improvement was observed in activities of daily living at 4-6 weeks.
- No significant treatment effects were found for emotional state or global assessment; adverse events were minimal and comparable to placebo.
Conclusions:
- Selegiline has proven disappointing for Alzheimer's disease, despite initial promise and use in Parkinson's disease.
- No clinically meaningful benefit was observed across various outcome measures (cognition, mood, daily living, global assessment).
- Current evidence does not support the use of selegiline for Alzheimer's disease treatment or further efficacy studies.
More Related Videos
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...